
|Articles|July 1, 2004
Studies explore anecortave acetate to treat, prevent CNV
Fort Lauderdale, FL-A series of studies is evaluating the angiostatic cortisene compound anecortave acetate (Retaane, Alcon Laboratories) as both a prophylactic and therapeutic intervention for choroidal neovascularization (CNV) in eyes with age-related macular degeneration (AMD), said Jason S. Slakter, MD, at the annual meeting of the Association for Research in Vision and Ophthalmology.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
4
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
5



























